Company: GEHC
Filing Date: 2025-06-05
Form Type: 424B2
Source: 0001193125-25-135863
Chunk: 14

Company: GE HealthCare Technologies Inc.
Filing Date: 2025-06-05
Form: 424B2
Chunk 14
---
 of the holders of the
notes, create and issue additional notes of any series, which will be equal in rank to the outstanding notes of such series in all material respects so that the new notes may be consolidated and form a single series with the notes and have the same
terms and conditions as to status, redemption or otherwise (except for the issue date, the public offering price and, in some cases, the first interest payment date, as described under “Description of the Notes—Additional Issues”) as
the notes of such series. If the additional notes of any series, if any, are not fungible with the notes of the applicable series offered hereby for U.S. federal income tax purposes, the additional notes of such series will have a separate CUSIP
number.

An increase in market interest rates could result in a decrease in the market value of the notes.

The condition of the financial markets and prevailing interest rates have fluctuated in the past and are likely to fluctuate in the future,
which could have an adverse effect on the market prices of the notes. In general, as market interest rates rise, debt securities bearing interest at fixed rates of interest decline in value. Consequently, if you purchase notes bearing interest at
fixed rates of interest and market interest rates increase, the market values of those notes may decline. We cannot predict the future level of market interest rates.

S-7

USE OF PROCEEDS

We estimate that the net proceeds to us from this offering will be approximately $1,487 million, after deducting the underwriting
discounts and estimated offering expenses payable by us.

We expect to use the net proceeds from this offering, together with cash on
hand, to repay the $1,500 million aggregate principal amount outstanding of the 2025 notes, and pay accrued interest, related premiums, fees and expenses in connection therewith. Pending the final application of the net proceeds of this
offering, we may use such proceeds temporarily for general corporate purposes.

Certain of the underwriters or their respective affiliates
may hold some of the 2025 notes being repaid and, accordingly, may receive a portion of the net proceeds of this offering. See “Underwriting.”

S-8

CAPITALIZATION The following table sets forth our consolidated cash, cash equivalents and restricted cash and our capitalization, in each case as of March 31, 2025, (i) on an actual basis, and (ii) as adjusted to give effect to this offering and the use of proceeds therefrom